Company intelligence / Profile preview

Stelmi

Normandy, France

Ownership: Private
Development stage: Other

Overview

Stelmi manufactured elastomer primary packaging components for injectable drug delivery, primarily stoppers and closures for vials and syringes, which are essential for maintaining drug integrity for sensitive and high-value pharmaceuticals. After its 2012 acquisition by AptarGroup, operations continued under the Aptar Pharma business line, now branded as Aptar Stelmi, with an ongoing focus on primary packaging for parenteral applications such as biologics, cytotoxics, monoclonal antibodies, vaccines, and other injectables[1][2][4][8].

Industry: Chemicals & Materials

Partnerships

Pharmaceutical companies using Aptar Stelmi containers and stoppers for injectables[4].

Beyond the preview

Go deeper on Stelmi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stelmi.

Explore the full profile